BerGenBio ASA (OTCPK:BRRGF)
$ 2.5 0 (0%) Market Cap: 27.51 Mil Enterprise Value: 17.20 Mil PE Ratio: 0 PB Ratio: 1.73 GF Score: 59/100

Q4 2020 Bergenbio ASA Earnings Call Transcript

Feb 10, 2021 / 09:00AM GMT
Release Date Price: $394
Richard Godfrey
BerGenBio ASA - CEO

Good morning, and welcome to BerGenBio's 2020 Quarter 4 and Year-End Report, Highlights and Financial Summary. My name is Richard Godfrey, and I'm the CEO of BerGenBio. I'm joined this morning by Rune Skeie, our CFO; and Hani Gabra, our Chief Medical Officer.

Our presentation and our quarterly report can be found on our website. Next slide, please. I should draw your attention to our forward-looking statements and safe harbor comments on Slide 2.

Next slide, please. We have quite a broad agenda today. To introduce you to our recent highlights, a summary of our biotechnology around AXL tyrosine kinase and our lead candidate bemcentinib, an update on our clinical trials, a comment on tilvestamab, our anti-AXL monoclonal antibody, a report on our financial status and an outlook for 2021.

Next slide, please. As a way of a reminder and introduction to BerGenBio, we are world leaders in understanding the role and function of AXL tyrosine kinase, specifically as it mediates aggressive diseases, including immune-evasive therapy resistant and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot